Plain-English translation of NCT07404865 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new medication designed to calm an overactive part of the immune system called B cells that cause primary Sjögren's disease. Sjögren's is an autoimmune condition where the immune system attacks moisture-producing glands, causing severe dry eyes and dry mouth. The medication works by blocking signals that make B cells attack the body, with the goal of reducing symptoms and disease activity.
Primary Sjögren's disease can be very uncomfortable and disabling, and current treatments don't work well for everyone. This trial exists to see if this new treatment can offer better relief by targeting the root cause of the disease at the immune level.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication or a placebo (inactive treatment) and will not know which one you're getting. You'll visit the study clinic regularly to receive your treatment, have blood tests, and answer questions about your symptoms. The study will track how your dry eyes and dry mouth improve and monitor for any side effects over several months.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States